Cardiac transplantation at the University of Pittsburgh: 1994 update. 1994

S M Pham, and R L Kormos, and S Murali, and A Kawai, and A J Demetris, and B G Hattler, and P A Williams, and D McNamara, and W Rosenblum, and F J Fricker
University of Pittsburgh, Pennsylvania, USA.

During the past 14 years, 746 hearts have been transplanted at the University of Pittsburgh. Immunosuppression has evolved from a CsA-based protocol with or without lympholytic prophylaxis to a tacrolimus-based protocol. Tacrolimus offers comparable survival to the conventional immunosuppression but is associated with lesser side effects and lower recurrent rejection. It also serves as an effective rescue agent for intractable rejection in patients receiving CsA-based immunosuppression. However, the shortage of donors, chronic rejection, and the morbidity associated with chronic use of nonspecific immunosuppression remain the major limitations in clinical transplantation. Currently, research at the University of Pittsburgh focuses on the induction of donor-specific transplantation tolerance in order to eliminate the morbidity associated with nonspecific immunosuppression and on left ventricular-assist devices as a bridge and/or an alternative to cardiac transplantation.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D008232 Lymphoproliferative Disorders Disorders characterized by proliferation of lymphoid tissue, general or unspecified. Duncan's Syndrome,X-Linked Lymphoproliferative Syndrome,Duncan Disease,Epstein-Barr Virus Infection, Familial Fatal,Epstein-Barr Virus-Induced Lymphoproliferative Disease In Males,Familial Fatal Epstein-Barr Infection,Immunodeficiency 5,Immunodeficiency, X-Linked Progressive Combined Variable,Lymphoproliferative Disease, X-Linked,Lymphoproliferative Syndrome, X-Linked, 1,Purtilo Syndrome,X-Linked Lymphoproliferative Disease,X-Linked Lymphoproliferative Disorder,Disease, Duncan,Disease, X-Linked Lymphoproliferative,Diseases, X-Linked Lymphoproliferative,Disorder, Lymphoproliferative,Disorder, X-Linked Lymphoproliferative,Disorders, Lymphoproliferative,Disorders, X-Linked Lymphoproliferative,Epstein Barr Virus Induced Lymphoproliferative Disease In Males,Epstein Barr Virus Infection, Familial Fatal,Familial Fatal Epstein Barr Infection,Immunodeficiency 5s,Immunodeficiency, X Linked Progressive Combined Variable,Lymphoproliferative Disease, X Linked,Lymphoproliferative Diseases, X-Linked,Lymphoproliferative Disorder,Lymphoproliferative Disorder, X-Linked,Lymphoproliferative Disorders, X-Linked,Lymphoproliferative Syndrome, X-Linked,Lymphoproliferative Syndromes, X-Linked,Purtilo Syndromes,Syndrome, Purtilo,Syndrome, X-Linked Lymphoproliferative,Syndromes, Purtilo,Syndromes, X-Linked Lymphoproliferative,X Linked Lymphoproliferative Disease,X Linked Lymphoproliferative Disorder,X Linked Lymphoproliferative Syndrome,X-Linked Lymphoproliferative Diseases,X-Linked Lymphoproliferative Disorders,X-Linked Lymphoproliferative Syndromes
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010414 Pennsylvania State bounded on the north by New York and Lake Erie, on the east by Delaware and New Jersey, on the south by Delaware and Maryland, and on the west by Ohio and West Virginia.
D002423 Cause of Death Factors which produce cessation of all vital bodily functions. They can be analyzed from an epidemiologic viewpoint. Causes of Death,Death Cause,Death Causes

Related Publications

S M Pham, and R L Kormos, and S Murali, and A Kawai, and A J Demetris, and B G Hattler, and P A Williams, and D McNamara, and W Rosenblum, and F J Fricker
January 1994, Clinical transplants,
S M Pham, and R L Kormos, and S Murali, and A Kawai, and A J Demetris, and B G Hattler, and P A Williams, and D McNamara, and W Rosenblum, and F J Fricker
November 1996, Nihon Geka Gakkai zasshi,
S M Pham, and R L Kormos, and S Murali, and A Kawai, and A J Demetris, and B G Hattler, and P A Williams, and D McNamara, and W Rosenblum, and F J Fricker
January 1991, Clinical transplants,
S M Pham, and R L Kormos, and S Murali, and A Kawai, and A J Demetris, and B G Hattler, and P A Williams, and D McNamara, and W Rosenblum, and F J Fricker
June 1994, Transplantation proceedings,
S M Pham, and R L Kormos, and S Murali, and A Kawai, and A J Demetris, and B G Hattler, and P A Williams, and D McNamara, and W Rosenblum, and F J Fricker
January 2011, Clinical transplants,
S M Pham, and R L Kormos, and S Murali, and A Kawai, and A J Demetris, and B G Hattler, and P A Williams, and D McNamara, and W Rosenblum, and F J Fricker
January 2011, Clinical transplants,
S M Pham, and R L Kormos, and S Murali, and A Kawai, and A J Demetris, and B G Hattler, and P A Williams, and D McNamara, and W Rosenblum, and F J Fricker
January 1992, Clinical transplants,
S M Pham, and R L Kormos, and S Murali, and A Kawai, and A J Demetris, and B G Hattler, and P A Williams, and D McNamara, and W Rosenblum, and F J Fricker
January 2004, Clinical transplants,
S M Pham, and R L Kormos, and S Murali, and A Kawai, and A J Demetris, and B G Hattler, and P A Williams, and D McNamara, and W Rosenblum, and F J Fricker
February 1994, Transplantation proceedings,
S M Pham, and R L Kormos, and S Murali, and A Kawai, and A J Demetris, and B G Hattler, and P A Williams, and D McNamara, and W Rosenblum, and F J Fricker
January 1999, Clinical transplants,
Copied contents to your clipboard!